Study of Ezefeno in patients with high cholesterol and type 2 diabetes
Part of Hormones & metabolism clinical trials.
This trial tests a medicine called Ezefeno to see if it helps lower cholesterol in people with type 2 diabetes who are already on statins. It may be an option if you have high triglycerides and other heart risk factors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes (as diagnosed by standard criteria).
- You are 19 years or older.
- Your non-HDL cholesterol is 100 mg/dL or higher and triglycerides are between 200 and 500 mg/dL while on a moderate-strength statin.
- You have at least one other heart risk factor (like high blood pressure, smoking, or family history).
- You are not pregnant or breastfeeding, your blood sugar is not severely out of control, and you do not have certain liver or muscle problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if pitavastatin alone or with ezetimibe affects blood sugar differently than atorvastatin in people who have heart or blood vessel disease and metabolic syndrome but do not have diabetes.
This trial studies whether high-intensity statin plus ezetimibe can improve heart health in people who do not have symptoms but have calcium buildup in their heart arteries. It may help lower cholesterol and reduce future heart risks for the right participants.
This study watches how well a combination cholesterol medication (pitavastatin and ezetimibe) works in people who have high cholesterol and metabolic syndrome (a cluster of health issues including high blood pressure, blood sugar, and cholesterol). You'll be monitored over time to see if the medication helps and is safe for you.
This trial tests a combination pill of two cholesterol-lowering medicines (pitavastatin and ezetimibe) in adults who have been taking either atorvastatin or rosuvastatin for at least 3 months. It aims to see if switching to this new combination is safe and effective.
This trial compares a lower-dose cholesterol pill (rosuvastatin plus ezetimibe) to a higher-dose version of just rosuvastatin for people with mild to moderate heart artery blockages who have not had a stent or bypass. It aims to see which approach works better and is safer.
This trial looks at when and how to use cholesterol-lowering treatment soon after a heart attack. It may help people lower LDL (“bad” cholesterol) safely in the first days after an acute event.
Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.